

Subject Index

Adjuvant treatment, S22 (E11), S46 (28), S68 (117), S107 (256), S111 (272), S115 (289), S127 (322), S165 (464)
 Axillary lymph node dissection, S57 (75), S61 (87), S115 (289), S148 (408)
 Chemotherapy – *see* Chemotherapy
 Clinical practice/guidelines, S45 (25), S46 (28)
 Early breast cancer, S43 (19), S93 (204), S94 (207, 208), S132 (343)
 Endocrine therapy, S44 (22), S45 (25), S56 (67), S92 (202), S94 (208, 209), S97 (221), S98 (223), S116 (291), S133 (347, 349), S157 (443)
 High risk patients, S95 (212), S110 (267), S126 (321), S157 (443)
 Locally advanced disease, S66 (108), S69 (121), S92 (203), S150 (415), S159 (453)
 Metastatic/advanced breast cancer, S66 (109), S70 (123), S74 (140)
 Node negative patients, S110 (267), S149 (413)
 Pre-/perimenopausal patients, S44 (22), S94 (207), S95 (211)
 Quality of life, S84 (174), S134 (351)
 Radiotherapy, S46 (29), S105 (249), S133 (348), S149 (413), S151 (421)

Anastrozole – *see* Aromatase inhibitors

Angiogenesis, S159 (449), S163 (456)
 Prognostic factor, S87 (184)
 VEGF, S90 (194), S157 (444), S158 (448)

Apoptosis – *see* Tumour biology

Arimidex – *see* Aromatase inhibitors, anastrozole

Aromatase inhibitors, S43 (17), S44 (21), S111 (271)
 Adjuvant therapy, S43 (19), S45 (25), S46 (28), S74 (140), S92 (202), S116 (291), S133 (347)
 Anastrozole, S43 (19), S44 (23), S45 (25), S67 (112), S68 (116), S83 (171), S92 (202), S97 (221), S130 (339)
 Early breast cancer, S43 (19), S56 (67)
 Letrozole, S83 (171), S96 (216), S98 (223), S128 (328)
 Lipid blood parameters, S97 (221), S136 (360)
 Metastatic/advanced breast cancer, S68 (116), S92 (202), S96 (216), S97 (221), S98 (225)
 Neoadjuvant therapy, S83 (171), S116 (291)
 Post-menopausal patients, S44 (23), S67 (112), S68 (116), S92 (202), S96 (216), S97 (221), S98 (223, 225), S130 (339)
 Tamoxifen, S38 (11), S43 (19), S44 (20), S46 (28), S56 (68), S67 (112), S68 (116), S74 (140), S92 (202), S94 (209), S97 (221), S98 (223), S112 (275), S116 (291, 293), S120 (308), S128 (328), S130 (339), S133 (347, 349), S135 (355), S149 (413)

Axillary lymph nodes, S55 (64, 66), S57 (75), S58 (77), S59 (79, 81), S60 (86), S61 (89), S62 (91, 94), S104 (247), S136 (359)
 Lymphoedema, S53 (57), S132 (346)
 Scintigraphy, S58 (78), S59 (80), S61 (88)
 Ultrasonography, S58 (76), S59 (82)

Bcl-2, S107 (257), S110 (269), S116 (291), S159 (453)

Biopsy techniques, S62 (94), S63 (97, 99), S64 (100), S65 (105), S99 (227), S116 (290), S140 (379), S146 (401), S147 (406)
 Advanced breast biopsy instrumentation (ABBI), S140 (375), S141 (382), S142 (384)
 Core needle, S63 (96), S110 (269), S139 (373), S140 (375), S141 (382), S145 (396), S146 (402)
 Needle size, S106 (252), S145 (398)
 Radioguided biopsy, S59 (81), S60 (83, 84), S64 (102)
 Ultrasound guided biopsy, S143 (390), S144 (395)
 VAC mammotone, S144 (394, 395)
 Wire-guided, S63 (96)

Bisphosphonates, S73 (133)
 Pamidronate, S69 (119)
 Zoledronate, S69 (119)

Bone metastasis (*see also* Metastatic disease), S70 (124), S98 (223)
 Bisphosphonates, S69 (119), S73 (133)
 Radiotherapy, S70 (122)
 Response markers, S159 (450)

Breast conserving surgery, S16 (E8), S45 (27), S84 (174), S116 (290), S149 (414), S153 (428, 429)
 Breast reconstruction, S80 (161)
 Cosmesis, S103 (243), S105 (251), S151 (420)
 Ductal carcinoma in situ, S117 (296)
 Early breast cancer, S100 (231), S105 (249)
 Elderly/geriatric patients, S84 (177), S153 (428)
 Local recurrence, S100 (231), S103 (242), S105 (248)
 Neo-adjuvant chemotherapy, S71 (127), S92 (203), S128 (327)
 Radiotherapy, S46 (29), S89 (190, 191), S90 (193), S126 (320), S149 (411, 412, 414), S152 (424), S153 (429), S155 (435)
 Residual tumour, S100 (232), S102 (240)
 Ultrasound guided surgery, S99 (228)

Breast units, S39 (15), S49 (43), S125 (317), S153 (425)

c-erbB-2 – *see* Her-2/neu

Chemotherapy/adjuvant chemotherapy, S43 (18), S46 (28), S53 (58), S56 (70), S67 (113), S68 (115), S69 (120), S71 (127), S72 (131), S74 (137), S77 (151), S87 (183), S92 (203), S93 (204, 206), S95 (211), S97 (218), S100 (230), S126 (321), S127 (322, 325, 324), S128 (329), S152 (424)
 Adriamycine, S94 (210)
 Antracyclines, S97 (220)
 Bisphosphonates, S69 (119)
 Chemosensitivity prediction, S94 (208), S107 (257), S110 (267)
 Doxorubicin, S52 (51), S68 (118), S94 (210)
 Epirubicin, S66 (111), S68 (117)
 High dose, S95 (212)
 High risk patients, S95 (212)
 Neoadjuvant chemotherapy, S65 (106), S66 (108), S69 (121), S73 (134), S110 (268), S128 (326, 327), S150 (415), S154 (430)
 Peri-operative chemotherapy, S52 (51)
 Predictive factors, S93 (205), S110 (267), S116 (292)
 Toxicity and side effects, S71 (126), S73 (136), S95 (212), S96 (214), S126 (319), S130 (339), S131 (342), S132 (343, 344, 345), S133 (347, 348, 349, 350), S134 (354), S135 (355, 357, 358), S136 (360)

Clinical practice/guidelines/attitudes, S49 (40), S81 (164), S82 (169), S121 (311), S147 (406), S152 (424)
 Adjuvant therapy, S45 (25)
 General practice – education, S75 (143)
 Quality control, S60 (86), S81 (165)

Clodronate – *see* Bisphosphonates

Diagnosis, S8 (E4), S39 (13, 15), S46 (31), S47 (32, 34, 35), S137 (364, 365), S138 (367, 368, 369, 370), S139 (371, 374), S140 (377, 378), S141 (380, 381, 383), S142 (385, 386, 387), S143 (388, 389, 390, 391), S144 (393, 394), S145 (397, 399), S146 (403), S148 (407, 408, 409, 410)
 Atypical ductal hyperplasia, S38 (8), S48 (36)
 Benign mammograms, S21 (E10)
 Biopsy techniques, S139 (373), S140 (375), S141 (382), S142 (384), S144 (395), S145 (396, 398), S146 (400, 401, 402), S147 (406)
 Delayed diagnosis, S144 (392), S146 (403)
 Familial cancer, S136 (363)
 Metastasis, S88 (186), S108 (262), S140 (376)
 Phylloides tumour, S151 (418)
 Self-examination, S137 (366), S139 (372)
 Triple diagnostic approach, S140 (379)

- Diagnostic Imaging**, S38 (6), S39 (13), S50 (45, 46), S57 (75), S58 (77), S61 (88, 90), S63 (98), S84 (176), S115 (287), S138 (368), S139 (371), S141 (380), S142 (384), S143 (388), S144 (393), S145 (399), S146 (400, 403)
 Cost-effectiveness, S37 (3), S38 (10), S51 (49), S83 (172)
 Digital mammography, S14 (E7), S31 (E15), S46 (31, 30), S140 (378), S144 (394, 395)
 Lymphoscintigraphy, S58 (78), S59 (80), S63 (99), S64 (101), S148 (408), S155 (437)
 Magnetic resonance, S38 (10), S47 (32), S51 (50), S62 (91), S115 (286), S138 (367, 370), S142 (387), S143 (389, 391)
 Non-screening setting, S46 (31)
 Scintimammography, S115 (286, 287), S143 (391)
 Ultrasonography, S47 (34), S58 (76), S59 (82), S99 (228), S139 (372), S140 (377), S141 (381), S142 (385), S143 (391)
- Docetaxel**, S66 (109), S67 (113), S68 (117, 118), S73 (136), S94 (210)
 Adjuvant therapy, S65 (107), S66 (108), S69 (121)
 Biweekly infusion, S107 (257)
 Doxorubicin, S52 (51), S66 (108, 109), S68 (118), S73 (134), S116 (293), S132 (343), S135 (357), S154 (430)
 Drug sequence, S94 (210)
 Metastatic/advanced disease, S52 (51), S66 (108, 109), S67 (113), S68 (117, 118), S72 (131), S73 (136)
 Neoadjuvant therapy, S65 (107), S66 (108), S69 (121), S154 (430)
 Preoperative treatment, S94 (210), S107 (257)
- Drug resistance**, S73 (135), S97 (220), S116 (293)
- Ductal carcinoma in situ**, S117 (294), S137 (364), S140 (378, 379), S150 (416)
 Adjuvant radiotherapy, S66 (108)
 Histopathology/classification, S47 (35), S118 (298, 299)
 Local recurrence, S117 (295), S118 (300)
 Predictive factors, S117 (296), S118 (300)
 Prognostic factors, S117 (297), S118 (299, 301, 302)
 Screening, S87 (180)
- Early breast cancer**, S37 (5), S43 (16), S56 (67), S62 (93), S63 (97), S76 (144), S81 (163), S107 (258), S108 (261), S109 (263), S131 (340), S159 (452), S163 (456)
 Adjuvant chemotherapy, S43 (19), S92 (202), S93 (204), S94 (207, 208), S132 (343)
 Adjuvant tamoxifen, S92 (202)
 Axillary lymph node dissection, S100 (230, 231), S106 (254)
 Breast conserving surgery, S100 (229, 231, 232), S153 (429), S155 (436)
 Elderly/geriatric patients, S92 (202)
 Mastectomy, S100 (229)
 Peri-operative chemotherapy, S128 (326)
 Radiotherapy, S89 (191), S149 (411, 412), S151 (419), S152 (424), S153 (426, 429), S155 (436)
- Elderly/geriatric patient care**, S37 (3), S66 (110), S67 (112), S80 (162), S82 (167), S92 (202), S96 (216), S111 (272), S128 (328), S144 (392), S150 (417)
 Breast reconstruction, S153 (428)
 Radiotherapy, S149 (411)
 Screening, S51 (48)
 Surgery, S84 (177)
- Endocrine therapy/adjuvant endocrine therapy**, S44 (21), S45 (25), S97 (219, 221), S98 (222, 224), S109 (264), S126 (321), S128 (328)
 Faslodex, S45 (24), S96 (216)
 Goserelin, S44 (22)
 Post-menopausal patients, S96 (216), S98 (223, 225)
 Raloxifene, S43 (16), S96 (217), S129 (332)
- EORTC trials**, S69 (119), S84 (174, 175), S100 (229), S108 (261), S126 (320), S128 (326), S131 (340), S134 (353), S147 (405), S149 (411), S151 (420)
- Epidemiological studies**, S87 (179), S28 (E14), S37 (3, 4), S45 (26), S50 (46), S51 (49, 48), S54 (60), S72 (129), S79 (157), S87 (180), S92 (200), S119 (305), S120 (306, 307), S121 (310, 311, 312), S122 (313), S125 (314, 317), S126 (318, 319), S127 (323), S129 (333), S139 (374), S165 (464, 465, 466, 467)
- Estrogen and progesterone receptors**, S43 (19), S44 (21), S55 (66), S94 (209), S98 (225), S107 (257), S110 (267)
 Adjuvant tamoxifen, S56 (68), S94 (209), S136 (360)
 Estrogen receptor-alpha, S53 (56), S54 (62), S96 (217), S114 (282)
 Estrogen receptor-beta, S53 (56), S54 (62), S96 (217)
- Immunohistochemistry, S53 (56)
 Predictive factor, S116 (291)
 Prognostic factor, S116 (293)
- Exemestane – see Aromatase inhibitors**
- Familial cancer/genetic testing**, S38 (8), S51 (50), S78 (152, 154), S80 (162), S119 (305), S157 (445)
 BRCA1/BRCA2 carriers, S38 (9), S54 (60), S99 (226), S136 (363)
 BRCA1/BRCA2 prevalence/screening, S38 (9), S136 (363), S163 (457)
 Diagnosis, S163 (457)
 Genetic counselling, S77 (148, 150)
 Ipsilateral/contralateral tumour incidence, S99 (226)
 MRI imaging, S51 (50)
 Ovarian cancer, S77 (150)
 Patient/family communication, S75 (143)
 Prophylactic surgery, S83 (170)
- Goserelin – see Endocrine therapy**
- Her-2/neu**, S52 (51, 53), S111 (270), S157 (443)
 Herceptin, S69 (120), S112 (274)
 Predictive/prognostic factor, S109 (264), S110 (267)
- Herceptin**, S88 (185), S109 (264), S112 (274)
 Metastatic disease, S69 (120), S95 (213), S131 (341)
 Toxicity and side effects, S96 (214)
 Tumour biology, S48 (37)
- Hormone replacement therapy**, S120 (308), S158 (446)
 Risk factor, S38 (11), S50 (44), S80 (160), S120 (309), S137 (365)
- Immunology and Immunotherapy**, S55 (64, 65), S56 (67), S57 (73)
 Dendritic cells, S55 (63)
 Immunotherapy, S57 (72), S109 (264)
 MUC-1, S56 (69)
 Vaccines, S52 (53)
- Letrozole – see Aromatase inhibitors**
- Lymphoedema**, S49 (43), S134 (352), S135 (356), S136 (361)
 Prevalence, S137 (364)
- Male breast cancer**, S74 (140), S165 (465)
- Metastatic/advanced breast cancer**, S10 (E5), S23 (E12), S72 (132), S73 (135), S74 (139), S96 (215), S97 (220)
 Gemcitabine, S72 (130), S74 (138)
- Nursing**, S49 (42), S76 (144, 145, 146), S79 (158), S80 (159, 162), S82 (167), S91 (199), S103 (241), S113 (280), S136 (362), S154 (433)
- Paclitaxel**
 Adjuvant therapy, S73 (134), S88 (185)
 Metastatic/advanced breast cancer, S72 (132), S73 (134, 135), S95 (213)
- Palliative care**, S49 (41), S68 (115), S70 (124), S74 (137), S75 (141), S78 (153), S91 (199)
- Pathology**, S39 (15), S47 (35), S48 (36, 38, 39), S52 (51, 52, 54), S53 (55, 56), S54 (61), S55 (63, 64), S61 (89), S63 (99), S64 (100), S114 (283), S116 (290), S118 (298, 299), S139 (373), S141 (383), S143 (388), S145 (398), S146 (401, 402), S147 (404, 406), S148 (409, 410), S156 (438, 441), S158 (446), S160 (454), S164 (463)
 Apoptotic index, S129 (332), S156 (439), S159 (453)
 Invasive lobular cancer – tumour grade, S37 (5), S141 (383)
- Phylloides tumour**, S151 (418)
- Predictive factors**, S94 (207), S112 (276), S113 (280, 281), S115 (289), S116 (292), S117 (296), S118 (300), S119 (304), S125 (316), S157 (445), S163 (457), S164 (460)
 Estrogen receptor, S116 (291)
 Gene expression profiling, S91 (196), S164 (460, 461)
 Genetic markers – comparative genomic comparison, S163 (457)
 Her-2/neu, S109 (264), S116 (291)
 New markers, S111 (271)
 P53, S116 (291)
 Residual tumour, S107 (256)
 Response to therapy, S107 (257)
 Sentinel lymph node, S116 (290)
- Prevention**, S38 (11), S43 (16, 17), S119 (303), S138 (368), S164 (462)
 Chemoprevention, S43 (18, 19), S44 (20), S53 (58)
 Endocrine therapy, S120 (308), S136 (360)

Prognostic factors, S70 (125), S71 (128), S94 (208), S107 (256), S109 (263), S110 (269, 266), S113 (279, 278), S114 (285), S117 (297), S118 (299, 302), S126 (319), S128 (327), S137 (365), S163 (456), S164 (460)

Angiogenesis, S87 (184)

Axillary lymph node status, S62 (94), S63 (95), S89 (189), S108 (259), S114 (284)

Her-2/neu, S107 (258), S110 (267)

New markers, S108 (260), S111 (271), S116 (293)

P53, S107 (257, 258), S109 (265), S116 (291), S157 (444), S160 (455)

Plasminogen activator, S111 (272), S112 (277)

Young age (<35 yrs), S108 (261), S111 (273), S153 (427)

Psycho-oncology, S33 (E16), S83 (173), S84 (175), S130 (336)

Family life, S76 (147)

Follow-up, S136 (362)

Patient/family communications, S75 (141), S91 (198), S129 (334, 335), S130 (337)

Psychological morbidity, S78 (155), S113 (280)

Psychosocial support, S81 (166), S82 (168)

Public awareness, S75 (142), S79 (157)

Quality of life, S77 (149), S79 (156), S83 (171), S134 (351)

Surgeon communication, S76 (144, 145)

Radiotherapy/adjuvant radiotherapy, S12 (E6), S71 (128), S130 (338), S151 (419, 421), S152 (424), S154 (432), S155 (434, 435, 436)

Breast conserving therapy, S149 (412, 414), S151 (420), S152 (423)

Chemoradiotherapy, S133 (348), S149 (413)

Dose delivery, S92 (203), S153 (426), S154 (431)

Early breast cancer, S89 (191), S149 (411), S153 (429)

Intra-operative radiotherapy, S89 (190, 191), S90 (192, 193), S149 (414), S152 (422)

Metastatic disease, S70 (122)

Neoadjuvant radiotherapy, S150 (415)

Radiation-induced cancer, S164 (462)

Rare tumours, S164 (463)

Cystosarcoma phylloides, S151 (418)

Tubular carcinoma, S110 (266), S164 (463)

Screening, S4 (E2), S37 (1, 3), S38 (11), S50 (44, 45, 47), S118 (302), S120 (306), S136 (363), S138 (368, 369), S139 (371), S146 (403), S165 (467)

Adverse effects, S46 (29), S146 (400)

Cost effectiveness, S38 (6), S51 (49)

Elderly/geriatric patients, S51 (48)

Magnetic resonance imaging, S38 (10), S51 (50)

Quality assurance, S50 (47), S121 (310)

Recommendations, S50 (46), S78 (154)

Ultrasonography, S142 (385)

Sentinel lymph node, S58 (77), S59 (81), S60 (86), S61 (87, 89), S62 (92, 93, 94), S63 (96), S64 (101), S65 (105, 106), S88 (187), S89 (188, 189), S114 (284), S118 (298), S147 (406), S148 (407, 408, 409, 410), S156 (441)

Internal mammary, S63 (97)

Intra-operative pathology assessment, S59 (79), S63 (99), S64 (100)

Metastasis assessment, S57 (75)

Model of predictive value, S64 (103)

Predictive factors for involvement, S63 (95), S116 (290)

Pre-operative technique, S58 (76)

Radioguided surgery, S58 (78), S60 (84, 85), S65 (104)

Radiopharmaceutical/dye, S59 (80), S60 (83)

Radioactive tracers, S61 (88, 90), S63 (98), S64 (102)

Visualisation, S62 (91)

Ultrasound guided biopsy, S59 (82)

Signal transduction pathways – *see* Tumour biology

Surgery, S6 (E3), S67 (114), S79 (158), S100 (229), S101 (233, 234), S103 (242), S104 (245, 246, 247), S105 (249, 250, 251), S106 (252, 255), S118 (300), S152 (424)

Ambulatory surgery, S101 (234)

Breast reconstruction, S25 (E13), S80 (161), S101 (235, 236), S102 (238, 239), S103 (244), S106 (253)

Cancer recurrence, S100 (231), S105 (248)

Ductal carcinoma in situ, S118 (300)

Elderly/geriatric patient care, S84 (177)

Mastectomy, S52 (51), S67 (114), S83 (170), S99 (226), S100 (229), S101 (233), S102 (237, 239), S104 (247), S105 (250), S118 (298), S155 (434)

Quality assurance, S100 (230), S104 (246)

Sentinel lymph node dissection – *see* Sentinel lymph node

Small breast tumours, S60 (85), S65 (104), S99 (227, 228), S102 (237)

Ultrasound guided surgery, S99 (228)

Wound drainage, S63 (97), S79 (158), S104 (245)

Surgical margins – *see* Surgery

Tamoxifen therapy, S56 (68), S97 (221), S120 (308), S128 (328), S136 (360)

Adjuvant tamoxifen, S92 (202), S116 (291), S149 (413), S152 (424)

Endometrial effects, S133 (349)

Metastatic/advanced breast cancer, S68 (116)

Post-menopausal patients, S67 (112), S98 (223), S130 (339)

Predictive factor, S116 (293)

Toxicity and side effects, S133 (347), S135 (355)

Taxanes – *see* Docetaxel

Trastuzumab – *see* Herceptin

Tumour biology, S19 (E9), S37 (5), S43 (19), S47 (35), S48 (37, 38, 39), S52 (52, 54), S55 (65), S56 (69), S57 (74, 71), S114 (283), S115 (288), S129 (332), S147 (404), S156 (439, 441), S157 (442), S159 (451, 452), S160 (454), S163 (458)

Apoptosis, S158 (446)

Cell cycle, S56 (70), S91 (195)

Estrogen receptors, S43 (18), S56 (67, 68)

Gene expression, S53 (55), S125 (315), S156 (440), S160 (455), S163 (459), S164 (460)

Gene mutations, S54 (60)

Growth factors and receptors, S54 (59), S55 (65), S90 (194), S158 (447)

MUC-1, S56 (69)

P53, S157 (444)

Proteomics, S156 (438)

Tumour markers, S157 (442)

VEGF, S158 (448)

Zoladex – *see* Endocrine therapy, goserelin

Zoledronate – *see* Biphosphonates